News

recessively

Pi-Medical Ltd acquired ISO 13485:2012 certification by TuV Austria Hellas

OPTIWAND

OPTIWAND - Inverse Optimierung von Lärmschutzwanddimensionen

4124560545

Pi-Medical Ltd welcomes you to the first newsletter for 2012 and wishes everyone a creative year. Our company, within the framework of the global economic and developmental crisis, continues to develop its products in the field of oncology with constancy and responsibility.

Full text click here

(610) 703-9074

PI-Medical Ltd received a EUROSTARS grant. The project started in November 2011 and will run for 2 years.

Software Developer/Engineer position openning

PI-Medical has an immediate opening for a Software Developer/Engineer.

BiopSee® – transperineal stereotactic navigated prostate biopsy

In the recent years, prostate cancer was the most commonly diagnosed cancer in men. Currently secure diagnosis

Optimization technology in noise barriers design

Innovative optimization technology developed by Pi-Medical used for noise barriers design.

(918) 687-3060

A study on the dosimetric comparison between manual and inverse plans in HDR intracavitary/interstitial cervical cancer brachytherapy was published in the last issue of the J.

Radiobiological evaluation of the influence of dwell time modulation restriction in HIPO optimized HDR prostate brachytherapy implants

A study on the effect of dwell time restiction on the optimized prostate brachytherapy implants was published in the last issue of the J. of Contemporary Brachytherapy.

(575) 492-5576

(Veenendaal, 28 September 2010) Nucletron and MedCom GmbH & Pi-Medical Ltd, today signed a license agreement for the next generation seeds treatment planning module of Oncentra Prostate.
 

BiopSee® at ESTRO 2010 - A single system for total prostate cancer diagnosis & focal therapy plan

BiopSee® is going to be presented during the Industrial Exhibition at ESTRO Annual Congress: ESTRO 29  - 12th to 16th September 2010 Barcelona, Spain.




» News archive